Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $114,988.86 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Ross Moat sold 2,367 shares of the firm’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $48.58, for a total value of $114,988.86. Following the sale, the chief operating officer directly owned 12,029 shares of the company’s stock, valued at approximately $584,368.82. This represents a 16.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock traded down $1.91 during trading hours on Wednesday, hitting $47.03. 600,454 shares of the company’s stock traded hands, compared to its average volume of 647,366. Kiniksa Pharmaceuticals International, plc has a 12-month low of $18.25 and a 12-month high of $50.03. The stock has a market capitalization of $3.60 billion, a price-to-earnings ratio of 63.55 and a beta of 0.06. The company has a fifty day simple moving average of $45.75 and a 200-day simple moving average of $42.13.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $200.86 million. During the same period in the prior year, the business earned ($0.12) earnings per share. The company’s revenue for the quarter was up 65.0% compared to the same quarter last year. On average, analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on KNSA shares. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Wedbush lifted their price objective on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Canaccord Genuity Group started coverage on Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They issued a “buy” rating and a $62.00 price objective for the company. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and an average price target of $55.29.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC grew its holdings in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares in the last quarter. Osaic Holdings Inc. purchased a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at about $31,000. USA Financial Formulas purchased a new position in Kiniksa Pharmaceuticals International during the 3rd quarter valued at about $32,000. Smartleaf Asset Management LLC purchased a new position in Kiniksa Pharmaceuticals International during the 4th quarter valued at about $36,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new position in Kiniksa Pharmaceuticals International during the 4th quarter valued at about $41,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.